AC
CTSO icon

Avenir Corporation’s Cytosorbents Corp CTSO Stock Holding History

Avenir Corporation’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.95M Sell
5,215,776
-14,323
-0.3% -$9.78K 0.36% 26
2025
Q4 		$3.34M Buy
5,230,099
+147,261
+3% +$113K 0.36% 25
2025
Q3 		$4.75M Buy
5,082,838
+24,301
+0.5% +$23.9K 0.49% 22
2025
Q2 		$6.47M Buy
5,058,537
+13,619
+0.3% +$13.7K 0.67% 22
2025
Q1 		$5.04M Buy
5,044,918
+1,950,972
+63% +$2.06M 0.53% 23
2024
Q4 		$2.82M Buy
3,093,946
+118,387
+4% +$116K 0.29% 28
2024
Q3 		$4.46M Buy
2,975,559
+5,297
+0.2% +$5.81K 0.45% 23
2024
Q2 		$2.09M Sell
2,970,262
-202,434
-6% -$176K 0.2% 26
2024
Q1 		$3.01M Buy
3,172,696
+121,294
+4% +$118K 0.26% 25
2023
Q4 		$3.39M Buy
3,051,402
+334,005
+12% +$496K 0.29% 23
2023
Q3 		$5.11M Sell
2,717,397
-2,335
-0.1% -$6.7K 0.48% 23
2023
Q2 		$9.76M Buy
2,719,732
+164,179
+6% +$519K 0.86% 20
2023
Q1 		$8.61M Buy
2,555,553
+108,464
+4% +$326K 0.81% 20
2022
Q4 		$3.79M Buy
2,447,089
+132,235
+6% +$196K 0.38% 24
2022
Q3 		$3.15M Buy
2,314,854
+149,855
+7% +$293K 0.33% 25
2022
Q2 		$4.74M Sell
2,164,999
-11,510
-0.5% -$26.4K 0.45% 25
2022
Q1 		$6.94M Buy
2,176,509
+389,234
+22% +$1.39M 0.55% 25
2021
Q4 		$7.49M Buy
1,787,275
+391,890
+28% +$2.2M 0.58% 23
2021
Q3 		$11.3M Buy
1,395,385
+28,836
+2% +$234K 0.95% 22
2021
Q2 		$10.3M Buy
1,366,549
+1,007,679
+281% +$8.49M 0.82% 24
2021
Q1 		$3.12M Buy
358,870
+152,130
+74% +$1.45M 0.27% 30
2020
Q4 		$1.65M Buy
206,740
+16,500
+9% +$138K 0.16% 38
2020
Q3 		$1.52M Buy
190,240
+22,520
+13% +$203K 0.16% 38
2020
Q2 		$1.66M Buy
167,720
+17,120
+11% +$157K 0.19% 37
2020
Q1 		$1.16M Hold
150,600
– – 0.16% 41
2019
Q4 		$580K Hold
150,600
– – 0.06% 54
2019
Q3 		$758K Buy
150,600
+5,300
+4% +$30.8K 0.08% 52
2019
Q2 		$960K Buy
145,300
+58,060
+67% +$399K 0.1% 49
2019
Q1 		$660K Buy
87,240
+10,850
+14% +$84.5K 0.07% 52
2018
Q4 		$617K Buy
76,390
+34,135
+81% +$339K 0.08% 52
2018
Q3 		$545K Buy
42,255
+11,185
+36% +$140K 0.06% 56
2018
Q2 		$354K Buy
+31,070
New +$294K 0.04% 60

Other funds holding CTSO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
CBU
CIBC Bancorp USA Chicago, Illinois $74.4B AUM

Avenir Corporation's CTSO Position: Q1 2026 in Review

Avenir Corporation reduced its Cytosorbents Corp (CTSO) stake by 0.27% in Q1 2026, selling an estimated $9.78K and leaving 5,215,776 shares worth $2.95M. The position accounts for 0.36% of the portfolio, ranked #26.

Avenir Corporation first reported a position in CTSO in Q2 2018 and has held it in 32 quarters since. The position peaked at $11.3M in Q3 2021. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.

  • Avenir Corporation held 5,215,776 shares of Cytosorbents Corp worth $2.95M as of Q1 2026.
  • Avenir Corporation sold 14,323 Cytosorbents Corp shares in Q1 2026, an estimated $9.78K.
  • Cytosorbents Corp made up 0.36% of Avenir Corporation's portfolio in Q1 2026, its #26 holding.
  • Avenir Corporation first reported a position in Cytosorbents Corp in Q2 2018 and has held it in 32 quarters since.
  • Avenir Corporation's Cytosorbents Corp position peaked at $11.3M in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.

Based on Avenir Corporation's 13F filing for Q1 2026, filed 14 May 2026.